Skip to main content
. Author manuscript; available in PMC: 2020 May 8.
Published in final edited form as: Neuropeptides. 2019 Jan 8;74:52–59. doi: 10.1016/j.npep.2019.01.002

Figure 4. (A).

Figure 4.

Shows the inhibitory effect of rosiglitazone (Rosi, 10 μM) and 15d-PGJ2 (10 μM) on substance P-induced histamine release. The selective PPAR-γ receptor antagonist, GW 9662 (1 μM) prevented the inhibitory effects of rosiglitazone and 15d-PGJ2. Percent histamine release is displayed relative to substance P-induced effects, which were set at 100%. (B) Shows that both rosiglitazone and 15d-PGJ2 had no effect on histamine release induced by compound 48/80. (C) Shows that ciglitazone and pioglitazone had no effect on histamine release induced by substance P. Values are mean ± SEM. * = p<0.05 versus substance P (A) or versus control (B). Note that SP release is set at 100% in (A) and (C).